Shay Boloor(@StockSavvyShay):$TEM expanded its multi year deal with $MRNA and $MRK to support potential commercialization of intismeran autogene with sequencing and sample logistics tied to each patient. Great to see Tempus moving directly into therapy design and manufacturing with a test tied to every treatment and a relationship that becomes much harder to replace once built into the process.

Shay Boloor

@StockSavvyShay

Chief Market Strategist @FuturumEquities | Regular on @Reuters, @YahooFinance, @Bloomberg, @FoxBusiness, @SchwabNetwork & @Forbes | NIA

Joined February 2019

337 Following 460.8K Followers

Shay Boloor@StockSavvyShay

2026.10.07 12:43

$TEM expanded its multi year deal with $MRNA and $MRK to support potential commercialization of intismeran autogene with sequencing and sample logistics tied to each patient. Great to see Tempus moving directly into therapy design and manufacturing with a test tied to every treatment and a relationship that becomes much harder to replace once built into the process.